The Journal of dermatological treatment最新文献_第7页

Toward the definition of moderate psoriasis: an expert opinion. 关于中度牛皮癣的定义：专家意见。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-23 DOI: 10.1080/09546634.2026.2626219

Antonio Costanzo, Federico Bardazzi, Martina Burlando, Anna Campanati, Carlo Carrera, Paolo Dapavo, Marco Galluzzo, Luigi Gargiulo, Paolo Gisondi, Francesco Loconsole, Piergiorgio Malagoli, Matteo Megna, Giuseppe Micali, Stefano Piaserico

{"title":"Toward the definition of moderate psoriasis: an expert opinion.","authors":"Antonio Costanzo, Federico Bardazzi, Martina Burlando, Anna Campanati, Carlo Carrera, Paolo Dapavo, Marco Galluzzo, Luigi Gargiulo, Paolo Gisondi, Francesco Loconsole, Piergiorgio Malagoli, Matteo Megna, Giuseppe Micali, Stefano Piaserico","doi":"10.1080/09546634.2026.2626219","DOIUrl":"10.1080/09546634.2026.2626219","url":null,"abstract":"Background: The clinical definition of moderate psoriasis is debated, affecting treatment eligibility and patient outcomes.Objective: A panel of Italian dermatologists aimed to propose practical criteria to define moderate psoriasis, based on a comprehensive literature review and clinical experience.Methods: The panel reviewed publications between 2016 and 2024 focusing on key severity scores, including the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), and Physician's Global Assessment (PGA), along with special area involvement and patient-reported outcomes.Results: Despite variability among studies, and the lack of universally accepted thresholds, the panel defined moderate psoriasis as a BSA of 5%-10%, DLQI of 5-10, a PGA score of 3, and involvement of at least two special areas (e.g. scalp, face, genitals, nails, hands, or feet). Distressing itch and psychosocial impact were also recognized as critical elements influencing perceived disease burden. A composite PGA-based approach, integrating objective measures with patient-centered criteria, is proposed for identifying patients with moderate psoriasis who may benefit from systemic therapy.Conclusion: This pragmatic approach may help bridge the gap between guidelines and real-world clinical practice, ensuring more accurate treatment allocation and reducing undertreatment of psoriasis.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2626219"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases. 注射富血小板纤维蛋白作为无效线性吗啡的有效治疗选择：病例报告。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-03 DOI: 10.1080/09546634.2026.2631895

Xuechen Ai, Jun He, Pengfei Song, Jing Wang

{"title":"Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases.","authors":"Xuechen Ai, Jun He, Pengfei Song, Jing Wang","doi":"10.1080/09546634.2026.2631895","DOIUrl":"10.1080/09546634.2026.2631895","url":null,"abstract":"Objectives: Localized scleroderma, also called morphea, is an inflammatory cutaneous disorder characterized by sclerosis of the skin and underlying tissues. Morphea is currently classified into 4 subtypes: limited, generalized, linear and mixed. Linear morphea in an en coup de saber pattern (LScs) manifests as band-like, atrophic lesions predominantly affecting the frontoparietal area, leading to facial contour defects and skin pigmentation. However, pharmacological treatments for LScs are limited in meeting the aesthetic expectations of patients. Recently, autologous platelet concentrates have shown great therapeutic potential for tissue regeneration and wound healing, while few studies have been conducted on their use in LScs patients.Methods and results: We present the first report of two patients with inactive LScs that were improved by treatment with injectable platelet-rich fibrin (i-PRF), a second-generation autologous platelet concentrate. Satisfactory aesthetic outcomes were both achieved in two patients within 5 injection sessions, with only mild pain and transient erythema after injection.Conclusions: Injectable platelet-rich fibrin can be a novel, valid therapeutic alternative for morphea management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2631895"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do genetic deficiency states predict the effect of pharmacologic target blockade? 基因缺陷状态能预测药物靶点阻断的效果吗？

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-10-07 DOI: 10.1080/09546634.2026.2728531

Brett R Shaffer, Yash C Jani, Steven R Feldman

引用次数: 0

Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial. 大麻二酚油治疗银屑病的疗效和安全性：一项随机、双盲、安慰剂对照试验。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2025-12-29 DOI: 10.1080/09546634.2025.2604448

Wanjarus Roongpisuthipong, Theerawut Klangjareonchai, Sathit Kurathong, Anuvat Roongpisuthipong

{"title":"Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial.","authors":"Wanjarus Roongpisuthipong, Theerawut Klangjareonchai, Sathit Kurathong, Anuvat Roongpisuthipong","doi":"10.1080/09546634.2025.2604448","DOIUrl":"10.1080/09546634.2025.2604448","url":null,"abstract":"Background: The management of psoriasis presents challenges, prompting many patients to seek alternative treatments. Cannabidiol (CBD) has demonstrated potential antioxidant and anti-inflammatory properties which may offer therapeutic benefits for skin conditions.Objective: To evaluate the efficacy and safety of cannabidiol oil compared to placebo in chronic plaque psoriasis patients.Methods: The randomized, double-blind, placebo-controlled trial enrolled 28 participants, who were administered either oral CBD oil 60 mg/day or placebo. The primary outcome was the Psoriasis Area and Severity Index (PASI) score. Secondary outcomes encompassed disease severity, quality of life, and sleep parameters. Safety was monitored through adverse events and laboratory assessments.Results: The CBD group did not demonstrate a significant improvement in PASI scores. However, there was a notable reduction in itch scores by Week 8, and sleep onset latency decreased by Week 6, although this effect was not sustained. Adverse events were mild to moderate in nature and similar across both groups.Limitations: The study duration may not fully capture the long-term effects, and the race and disease severity may limit the generalizability of the findings. A larger sample size is suggested for future studies.Conclusion: Cannabidiol oil was well-tolerated; however, it did not result in a significant reduction in psoriasis severity. Temporary improvements in itch relief and sleep onset indicate that further research with higher doses and extended durations is warranted.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2604448"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Flumethasone-salicylic acid cream effectively flattened verrucous epidermal nevus: a case report. 氟米松-水杨酸乳膏有效扁平疣状表皮痣1例。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2025-12-29 DOI: 10.1080/09546634.2025.2603129

Yu Jiang, Wei Li, Shilin Deng, Qian Li, Wenyan Liu, Hui Ye, Jingyao Liang, Xibao Zhang

引用次数: 0

Moderate to severe Chronic Hand Eczema in clinical practice: etiological subtypes, clinical signs and symptoms, and comorbidities-results from the RWEAL study. 临床实践中的中重度慢性手部湿疹：病因亚型、临床体征和症状以及合并症——来自RWEAL研究的结果

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-06 DOI: 10.1080/09546634.2025.2603121

Maria Concetta Fargnoli, Sonja Molin, Anthony Bewley, Christian Apfelbacher, Lysel Brignoli, Alexanne Morillo, Eydna Didriksen Apol, Douglas Maslin, Marie-Noëlle Crépy, Ana Maria Giménez-Arnau

{"title":"Moderate to severe Chronic Hand Eczema in clinical practice: etiological subtypes, clinical signs and symptoms, and comorbidities-results from the RWEAL study.","authors":"Maria Concetta Fargnoli, Sonja Molin, Anthony Bewley, Christian Apfelbacher, Lysel Brignoli, Alexanne Morillo, Eydna Didriksen Apol, Douglas Maslin, Marie-Noëlle Crépy, Ana Maria Giménez-Arnau","doi":"10.1080/09546634.2025.2603121","DOIUrl":"10.1080/09546634.2025.2603121","url":null,"abstract":"Objectives: Effective management of moderate to severe Chronic Hand Eczema (CHE) requires improved understanding of its etiological subtypes, signs and symptoms, and comorbidities. The objective of this study was to investigate the clinical characteristics of patients with moderate to severe CHE.Methods: This was a multinational retrospective online chart review in Canada, France, Germany, Italy, Spain, and the UK. Physicians were asked to identify eligible patients from medical records to provide retrospective data over the past 12 months for up to 10 adult patients treated with topical corticosteroids (TCS) or for whom TCS were contraindicated.Results: A total of 292 physicians completed forms for 1939 patients (56.8% with moderate and 43.2% with severe CHE). The most frequent etiological subtypes were irritant contact dermatitis (40.1%), atopic dermatitis (33.1%) and allergic contact dermatitis (27.5%). Palms (56.6%), fingertips (41.6%) and backs of hands (40.8%) were the most affected areas. Erythema and pruritus were the most frequent signs and symptoms. A history of atopic dermatitis was reported for 43.8% of patients.Conclusions: In conclusion, patients with moderate to severe CHE present with multiple etiological subtypes and a range of signs and symptoms. Many patients had no atopic condition besides CHE, and no history of atopic dermatitis, indicating that CHE is not simply atopic dermatitis of the hands.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2603121"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort. 利桑单抗在中重度牛皮癣中的超级应答：多中心、国际、现实世界队列的患病率、预测因素和长期维持

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-22 DOI: 10.1080/09546634.2026.2617770

Diego Orsini, Luca Potestio, Matteo Megna, Chiara Assorgi, Antonio Costanzo, Annunziata Dattola, Maria Concetta Fargnoli, Paulo Ferreira, Ana Ferreirinha, Francesca Maria Gaiani, Dario Graceffa, Luciano Ibba, Ana Luísa João, Barbara Leal, Luiz Leite, Maria João Paiva Lopes, Martim Luz, Piergiorgio Malagoli, Pedro Mendes-Bastos, Francesco Messina, Alessandra Narcisi, Giovanni Pellacani, Rita Pimenta, Ângela Roda, Nello Tommasino, Joana Valério, Tiago Torres

{"title":"Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.","authors":"Diego Orsini, Luca Potestio, Matteo Megna, Chiara Assorgi, Antonio Costanzo, Annunziata Dattola, Maria Concetta Fargnoli, Paulo Ferreira, Ana Ferreirinha, Francesca Maria Gaiani, Dario Graceffa, Luciano Ibba, Ana Luísa João, Barbara Leal, Luiz Leite, Maria João Paiva Lopes, Martim Luz, Piergiorgio Malagoli, Pedro Mendes-Bastos, Francesco Messina, Alessandra Narcisi, Giovanni Pellacani, Rita Pimenta, Ângela Roda, Nello Tommasino, Joana Valério, Tiago Torres","doi":"10.1080/09546634.2026.2617770","DOIUrl":"10.1080/09546634.2026.2617770","url":null,"abstract":"Background/objectives: The concept of super responders (SRs) has gained increasing attention in psoriasis. However, evidence focusing exclusively on risankizumab remains limited. This multicenter, international, real-world study aimed to assess the prevalence, predictors, and long-term maintenance of SR status among patients with moderate-to-severe plaque psoriasis treated with risankizumab.Methods: A retrospective observational study was conducted across 10 Italian and Portuguese referral centers. SRs were defined as patients achieving complete skin clearance (PASI 0) at week 20. Predictors of SR achievement and maintenance were assessed using multivariate logistic regression models at weeks 52, 104, and 130 (2.5 years).Results: A total of 1372 patients were included (mean PASI 14.9 ± 8.2). At week 20, 610 (44.5%) achieved PASI 0 and were classified as SRs; 84.4% maintained this status at week 52 and 64.9% at 2.5 years. Biologic-naïve status (OR 1.65; p < 0.001) predicted SR achievement, whereas palmoplantar psoriasis (OR 0.58; p = 0.005) and higher BMI (OR 0.96; p = 0.011) negatively influenced it. Biologic-naïve status remained the strongest predictor of long-term maintenance (OR 2.87; p = 0.003).Conclusions: Risankizumab demonstrated high and sustained long-term effectiveness, inducing rapid and sustained complete clearance in a substantial proportion of patients.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2617770"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose escalation and personalization in atopic dermatitis: reply to the real-world study by Demirbaş et al. "Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.". 特应性皮炎的剂量递增和个体化：对demirbaat等人的真实世界研究的答复。JAK1抑制剂治疗特应性皮炎的剂量依赖性有效性和患者报告的结果：一项为期36周的多中心现实世界队列研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-05 DOI: 10.1080/09546634.2026.2627102

Luigi Gargiulo, Matteo Bianco, Luciano Ibba, Sara Di Giulio, Antonio Costanzo, Alessandra Narcisi

引用次数: 0

Surgery without postoperative adjuvant therapy for dissecting cellulitis of the scalp: a retrospective study of a selected cohort. 无术后辅助治疗的头皮夹层蜂窝织炎手术：一项选定队列的回顾性研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-28 DOI: 10.1080/09546634.2026.2739740

Junyou Zheng, Rundong Zhang, Ke Zhang, Qian Zhang, Yan Wang, Wenbo Bu, Binbin Hou

{"title":"Surgery without postoperative adjuvant therapy for dissecting cellulitis of the scalp: a retrospective study of a selected cohort.","authors":"Junyou Zheng, Rundong Zhang, Ke Zhang, Qian Zhang, Yan Wang, Wenbo Bu, Binbin Hou","doi":"10.1080/09546634.2026.2739740","DOIUrl":"https://doi.org/10.1080/09546634.2026.2739740","url":null,"abstract":"Background: Evidence regarding the efficacy of surgery without postoperative adjuvant therapy (SWPAT) for dissecting cellulitis of the scalp (DCS) remains limited, and objective biomarkers predicting postoperative outcomes are lacking.Objective: To describe clinical outcomes after SWPAT in a selected retrospective cohort and to explore the association between baseline IHS4 and recurrence.Methods: Fifty-eight DCS patients were analyzed. Receiver operating characteristic (ROC) analysis identified the optimal baseline IHS4 cutoff for recurrence prediction. Recurrence-free survival (RFS) was assessed by Kaplan-Meier analysis, and multivariable Cox proportional hazards models were constructed using a two-covariate-per-model strategy to mitigate overfitting.Results: SWPAT significantly improved IHS4, VAS, and DLQI scores (all p < 0.001). Baseline IHS4 predicted recurrence with an AUC of 0.823, yielding an optimal cutoff of 11.5. Patients were stratified into a low-risk group (LRG, IHS4 ≤ 11, n = 30) and a high-risk group (HRG, IHS4 ≥ 12, n = 28). Surgical approaches were balanced between groups (p = 0.869). The HRG showed significantly shorter RFS (log-rank p < 0.001), and HRG classification remained an independent predictor of recurrence after adjustment for disease duration.Conclusions: SWPAT delivers sustained benefits in this selected cohort. Baseline IHS4 ≥ 12 predicts postoperative recurrence in DCS, requiring prospective external validation and do not establish comparative efficacy.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2739740"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prurigo nodularis enters the biologic era: what has changed and what vixarelimab still must prove. 结节性痒疹进入了生物学时代：什么已经改变了，vixarelimab还必须证明什么。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-02 DOI: 10.1080/09546634.2026.2622858

Mohammed Shanshal

引用次数: 0